Table 1.

Antioxidants

Drugs	Type	Clinical Outcomes
NAC	Controlling oxidative stress	ClinicalTrials.gov, NCT01136239 (1-year high-dose NAC improved small airway function in COPD and reduced the frequency of exacerbations) ClinicalTrials.gov, NCT01739790 (The trial was 8 weeks and did not find that high-dose NAC improved respiratory clinical outcomes in COPD)
Sulforaphane	Targeting the Nrf2 gene	Clinicaltrials.gov, NCT01335971 (4 weeks of sulforaphane in COPD patients was not found to stimulate Nrf2 gene expression and was not found to improve inflammatory marker levels)